Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Sight Sciences, Inc.SGHT · Entity 5537 | Chief Financial Officer | October 02, 2026 | October 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Sight Sciences, Inc.
Report date October 02, 2026 · Filed October 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 216,829 |
Reported balance
After 2026-10-02 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-10-02 · Sale · Disposed 7,208 · Balance 216,829 F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3: Includes (i) 62,932 shares of Common Stock, and (ii) 153,897 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs").
F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: Includes (i) 62,932 shares of Common Stock, and (ii) 153,897 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 02, 2026 Filed Oct 5, 2026 20:42 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 7,208 | $8.85 | $63,812.42 |
DisclosureSEC source: 0001193125-26-414277 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 216,829 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.68 to $9.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 62,932 shares of Common Stock, and (ii) 153,897 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| July 02, 2026 Filed Jul 6, 2026 23:36 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 6,902 | $5.36 | $36,994.72 |
DisclosureSEC source: 0001193125-26-296596 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 224,037 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $5.19 to $5.46, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 55,200 shares of Common Stock, and (ii) 168,837 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| April 06, 2026 Filed Apr 9, 2026 21:17 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 7,231 | $3.55 | $25,670.05 |
DisclosureSEC source: 0001193125-26-149858 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 230,939 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("Common Stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units ("RSUs"). F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $3.43 to $3.58, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 47,160 shares of Common Stock, and (ii) 183,779 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| February 03, 2026 Filed Feb 5, 2026 21:48 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 86,940 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-039554 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 238,170 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing March 31, 2026 and continuing through December 31, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to $562,500 divided by the closing price of the Common Stock on the grant date, which was February 3, 2026. F2 · balance_after: Includes (i) 39,451 shares of Common Stock, and (ii) 198,719 shares of Common Stock which shall be acquired upon the vesting and settlement of RSUs that have not yet vested. Read SEC document |
| January 16, 2026 Filed Jan 21, 2026 21:55 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 2,616 | $6.62 | $17,317.92 |
DisclosureSEC source: 0001193125-26-018128 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 151,230 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share ("common stock"), sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of common stock were sold. The shares were sold in multiple transactions at prices ranging from $6.44 to $6.69, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. F3 · balance_after: Includes (i) 39,451 shares of common stock, and (ii) 111,779 shares of common stock which shall be acquired upon the vesting and settlement of restricted stock units ("RSUs") that have not yet vested. Read SEC document |
| January 06, 2026 Filed Jan 7, 2026 00:04 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 594 | $7.48 | $4,443.12 |
DisclosureSEC source: 0001193125-26-004987 · ownership.xml · nonDerivative · entry 2 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 153,846 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F3 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 05, 2026 Filed Jan 7, 2026 00:04 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 4,405 | $7.82 | $34,447.10 |
DisclosureSEC source: 0001193125-26-004987 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 154,440 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.71 to $7.97, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 21:19 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | SaleCommon Stock | 2,518 | $8.25 | $20,773.50 |
DisclosureSEC source: 0001193125-25-306746 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,845 F1 · shares: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units. F2 · price: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $8.16 to $8.36, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 21:34 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 15,337 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-25-280299 · ownership.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,363 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan. The RSUs vest in 16 equal quarterly installments commencing December 31, 2025 and continuing through September 30, 2029, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). The number of RSUs granted is equal to approximately $100,000 of shares of Common Stock as determined by the stock price on the grant date, November 11, 2025. The RSUs have no expiration date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantStock Option (Right to Buy) · Derivative | 14,400 | $0.00 Strike: $9.78 | $0.00 |
DisclosureSEC source: 0000899243-23-009241 · doc4.xml · derivative · entry 2 Rodberg James · CIK 0001961970 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,400 Underlying: Common Stock · 14,400 shares Expires 2033-03-16 F3 · shares: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. F3 · derivative.exercise_date: Reflects a grant of stock options ("Options") made to the Reporting Person under the 2021 Plan. The Options vest and become exercisable in 48 equal monthly installments with the first installment vesting commencing on January 1, 2023 through January 1, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| March 16, 2023 Filed Mar 21, 2023 10:15 UTC | Sight Sciences, Inc. SGHT · Entity 5537 | GrantCommon Stock | 20,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-009241 · doc4.xml · nonDerivative · entry 1 Rodberg James · CIK 0001961970 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 699 F1 · shares: Reflects a grant of restricted stock units ("RSUs") made to the Reporting Person under the Issuer's 2021 Incentive Award Plan (the "2021 Plan"). The RSUs vest in four equal annual installments from January 15, 2024 through January 15, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Each RSU represents a contingent right to receive one share of the Issuer's common stock, par value $0.001 per share ("Common Stock"). F2 · balance_after: Reflects shares of Common Stock beneficially owned by the Reporting Person as of the date hereof, excluding RSUs that do not vest within 60 days of this filing pursuant to Rule 13d-3(d)(1)(i). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.